Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia.

Academic Article

Abstract

  • Distinct sphingolipid metabolism of AML with MDS-related changes defines unique sensitivity to nanoliposomal C6-ceramide. Vinblastine alters sphingolipid metabolism to enhance the sensitivity of AML to nanoliposomal C6-ceramide.

    • Authors

  • Barth, Brian M
  • Wang, Weiyuan
  • Toran, Paul T
  • Fox, Todd E
  • Annageldiyev, Charyguly
  • Ondrasik, Regina M
  • Keasey, Nicole R
  • Brown, Timothy J
  • Devine, Viola G
  • Sullivan, Emily C
  • Cote, Andrea L
  • Papakotsi, Vasiliki
  • Tan, Su-Fern
  • Shanmugavelandy, Sriram S
  • Deering, Tye G
  • Needle, David
  • Stern, Stephan T
  • Zhu, Junjia
  • Liao, Jason
  • Viny, Aaron D
  • Feith, David J
  • Levine, Ross L
  • Wang, Hong-Gang
  • Loughran, Thomas P
  • Sharma, Arati
  • Kester, Mark
  • Claxton, David F

    • Status

    Publication Date

  • September 10, 2019

    • Has Subject Area

    Published In

  • Blood Adv  Journal

    • Keywords

  • Antineoplastic Agents, Phytogenic
  • Ceramides
  • Drug Carriers
  • Drug Delivery Systems
  • Humans
  • Leukemia, Myeloid, Acute
  • Liposomes
  • Nanostructures
  • Sphingolipids
  • Treatment Outcome
  • Vinblastine

    • Digital Object Identifier (doi)

    Start Page

  • 2598

    • End Page

  • 2603

    • Volume

  • 3

    • Issue

  • 17